HOW INDUSTRY LEADERS ARE SHAPING THE PATH TO 'VIKSIT BHARAT 2047'?

As India strives to achieve its ambitious goals under the Viksit Bharat 2047 initiatives, the vision and guidance of industry leaders are essential in navigating the path to economic growth, social progress, and sustainable development. Bringing you industry leaders who are playing a transformative role in shaping the path to Viksit Bharat by 2047.

- 

Dr. Satya Vadlamani, CMD of Murli Krishna Pharma, is a trailblazer in the Indian pharmaceutical industry, driving innovation, global expansion, and 'Make in India' excellence. With her visionary leadership, she has strengthened India's position on the global pharma map, fostering industry-academia collaboration to accelerate research and development. Her commitment to self- reliance aligns with the Viksit Bharat Mission, ensuring India emerges as a powerhouse in pharmaceutical innovation and manufacturing. Through her relentless pursuit of excellence, Dr. Vadlamani is not only transforming the industry but also contributing to India's journey towards becoming a developed nation.

As a key player in the pharmaceutical research and manufacturing sector, Murli Krishna Pharma Pvt Ltd (MKPPL) is committed to advancing healthcare, fostering innovation, and championing sustainability. Under the visionary leadership of Dr. Satya Vadlamani, CMD, the company has become a trailblazer in drug delivery technologies, playing a vital role in shaping India's aspirations of becoming a developed nation by 2047. By focusing on patient- centric solutions, global expansion, and public health initiatives, MKPPL is driving meaningful contributions to a healthier and economically stronger India.

Leadership in Drug Delivery Innovation

MKPPL began its journey by mastering microencapsulation techniques for controlled drug release and has since expanded into advanced drug delivery systems such as nanoparticles and nanoencapsulation. These cutting- edge technologies allow for targeted delivery of pharmaceutical compounds, enhancing both the efficacy and safety of treatments.